Phase III trial comparing 3–6 months of adjuvant FOLFOX4/XELOX in stage II–III colon cancer: safety and compliance in the TOSCA trialSara Lonardi, Lorenza Rimassa, L. Ciuffreda et al.|Annals of Oncology|2016Cited by 56
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trialGerardo Rosati, Giordano Beretta, Sara Lonardi et al.|European Journal of Cancer|2021Cited by 15
P1.01-053 Italian Nivolumab Expanded Access Programme (EAP): Data from Patients with Advanced Non-Squamous NSCLC and Brain MetastasesLucio Crinò, Angelo Delmonte, Paolo Bidoli et al.|Journal of Thoracic Oncology|2017Cited by 8
Efficacy and safety data from patients with advanced non-squamous NSCLC and brain metastases from the nivolumab expanded access programme (EAP) in ItalyLucio Crinò, Angelo Delmonte, Paolo Bidoli et al.|Annals of Oncology|2017Cited by 7
399O Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in elderly patients: A subgroup analysis from TOSCA trialGerardo Rosati, Roberto Labianca, Francesca Galli et al.|Annals of Oncology|2020Cited by 5